Claudio P. Santiago
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Claudio P. Santiago has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Brenden K. Petersen
Laboratory Lawrence Livermore National USA
1 shared publication - Brenden K. Petersen
Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
1 shared publication - Chase Cockrell
Department of Surgery, University of Vermont, Burlington, Vermont
1 shared publication - Daniel Faissol
Lawrence Livermore National Laboratory, Livermore, CA, United States
1 shared publication - Gary An
Department of Surgery, University of Vermont Larner College of Medicine
1 shared publication - Jiachen Yang
Georgia Institute of Technology
1 shared publication
Latest Publications
- Open Access
Deep symbolic regression: Recovering mathematical expressions from data via risk-seeking policy gradients
Discovering the underlying mathematical expressions describing a dataset is a core challenge for artificial intelligence. This is the problem of $\textit{symbolic regression}$. Despite recent advances in training neural networks to solve complex tasks, deep learning approaches to symbolic regression are underexplored. We propose a framework that leverages deep learning for symbolic regression via a simple idea: use a large model to search the space of small models. Specifically, we use a recurrent neural network to emit a distribution over tractable mathematical expressions and employ a novel risk-seeking policy gradient to train the network to generate better-fitting expressions. Our algorithm outperforms several baseline methods (including Eureqa, the gold standard for symbolic regression) in its ability to exactly recover symbolic expressions on a series of benchmark problems, both with and without added noise. More broadly, our contributions include a framework that can be applied to optimize hierarchical, variable-length objects under a black-box performance metric, with the ability to incorporate constraints in situ, and a risk-seeking policy gradient formulation that optimizes for best-case performance instead of expected performance.Open AccessDeep symbolic regression: Recovering mathematical expressions from data via risk-seeking policy gradients
Discovering the underlying mathematical expressions describing a dataset is a core challenge for artificial intelligence. This is the problem of $\textit{symbolic regression}$. Despite recent advances in training neural networks to solve complex tasks, deep learning approaches to symbolic regression are underexplored. We propose a framework that leverages deep learning for symbolic regression via a simple idea: use a large model to search the space of small models. Specifically, we use a recurrent neural network to emit a distribution over tractable mathematical expressions and employ a novel risk-seeking policy gradient to train the network to generate better-fitting expressions. Our algorithm outperforms several baseline methods (including Eureqa, the gold standard for symbolic regression) in its ability to exactly recover symbolic expressions on a series of benchmark problems, both with and without added noise. More broadly, our contributions include a framework that can be applied to optimize hierarchical, variable-length objects under a black-box performance metric, with the ability to incorporate constraints in situ, and a risk-seeking policy gradient formulation that optimizes for best-case performance instead of expected performance. - Open Access
Precision medicine as a control problem: Using simulation and deep reinforcement learning to discover adaptive, personalized multi-cytokine therapy for sepsis
Sepsis is a life-threatening condition affecting one million people per year in the US in which dysregulation of the body's own immune system causes damage to its tissues, resulting in a 28 - 50% mortality rate. Clinical trials for sepsis treatment over the last 20 years have failed to produce a single currently FDA approved drug treatment. In this study, we attempt to discover an effective cytokine mediation treatment strategy for sepsis using a previously developed agent-based model that simulates the innate immune response to infection: the Innate Immune Response agent-based model (IIRABM). Previous attempts at reducing mortality with multi-cytokine mediation using the IIRABM have failed to reduce mortality across all patient parameterizations and motivated us to investigate whether adaptive, personalized multi-cytokine mediation can control the trajectory of sepsis and lower patient mortality. We used the IIRABM to compute a treatment policy in which systemic patient measurements are used in a feedback loop to inform future treatment. Using deep reinforcement learning, we identified a policy that achieves 0% mortality on the patient parameterization on which it was trained. More importantly, this policy also achieves 0.8% mortality over 500 randomly selected patient parameterizations with baseline mortalities ranging from 1 - 99% (with an average of 49%) spanning the entire clinically plausible parameter space of the IIRABM. These results suggest that adaptive, personalized multi-cytokine mediation therapy could be a promising approach for treating sepsis. We hope that this work motivates researchers to consider such an approach as part of future clinical trials. To the best of our knowledge, this work is the first to consider adaptive, personalized multi-cytokine mediation therapy for sepsis, and is the first to exploit deep reinforcement learning on a biological simulation.
Open AccessPrecision medicine as a control problem: Using simulation and deep reinforcement learning to discover adaptive, personalized multi-cytokine therapy for sepsis
Sepsis is a life-threatening condition affecting one million people per year in the US in which dysregulation of the body's own immune system causes damage to its tissues, resulting in a 28 - 50% mortality rate. Clinical trials for sepsis treatment over the last 20 years have failed to produce a single currently FDA approved drug treatment. In this study, we attempt to discover an effective cytokine mediation treatment strategy for sepsis using a previously developed agent-based model that simulates the innate immune response to infection: the Innate Immune Response agent-based model (IIRABM). Previous attempts at reducing mortality with multi-cytokine mediation using the IIRABM have failed to reduce mortality across all patient parameterizations and motivated us to investigate whether adaptive, personalized multi-cytokine mediation can control the trajectory of sepsis and lower patient mortality. We used the IIRABM to compute a treatment policy in which systemic patient measurements are used in a feedback loop to inform future treatment. Using deep reinforcement learning, we identified a policy that achieves 0% mortality on the patient parameterization on which it was trained. More importantly, this policy also achieves 0.8% mortality over 500 randomly selected patient parameterizations with baseline mortalities ranging from 1 - 99% (with an average of 49%) spanning the entire clinically plausible parameter space of the IIRABM. These results suggest that adaptive, personalized multi-cytokine mediation therapy could be a promising approach for treating sepsis. We hope that this work motivates researchers to consider such an approach as part of future clinical trials. To the best of our knowledge, this work is the first to consider adaptive, personalized multi-cytokine mediation therapy for sepsis, and is the first to exploit deep reinforcement learning on a biological simulation.